These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21557669)

  • 1. Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.
    Picchio G; Vingerhoets J; Tambuyzer L; Coakley E; Haddad M; Witek J
    AIDS Res Hum Retroviruses; 2011 Dec; 27(12):1271-5. PubMed ID: 21557669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
    Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
    Vingerhoets J; Nijs S; Tambuyzer L; Hoogstoel A; Anderson D; Picchio G
    Antivir Ther; 2012; 17(8):1571-9. PubMed ID: 22869341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.
    Kagan RM; Sista P; Pattery T; Bacheler L; Schwab DA
    AIDS; 2009 Jul; 23(12):1602-5. PubMed ID: 19474648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
    Vingerhoets J; Tambuyzer L; Azijn H; Hoogstoel A; Nijs S; Peeters M; de Béthune MP; De Smedt G; Woodfall B; Picchio G
    AIDS; 2010 Feb; 24(4):503-14. PubMed ID: 20051805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
    Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
    J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
    Poveda E; de Mendoza C; Pattery T; González Mdel M; Villacian J; Soriano V
    AIDS; 2008 Nov; 22(17):2395-8. PubMed ID: 18981781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
    Varghese V; Shahriar R; Rhee SY; Liu T; Simen BB; Egholm M; Hanczaruk B; Blake LA; Gharizadeh B; Babrzadeh F; Bachmann MH; Fessel WJ; Shafer RW
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):309-15. PubMed ID: 19734799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.
    Agneskog E; Nowak P; Källander CF; Sönnerborg A
    J Med Virol; 2013 Apr; 85(4):703-8. PubMed ID: 23364785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.
    Oumar AA; Jnaoui K; Kabamba-Mukadi B; Yombi JC; Vandercam B; Goubau P; Ruelle J
    Acta Clin Belg; 2010; 65(4):242-4. PubMed ID: 20954462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Etravirine: genetic barrier and resistance development].
    Llibre JM; Santos JR; Clotet B
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
    Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
    HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
    Gupta S; Vingerhoets J; Fransen S; Tambuyzer L; Azijn H; Frantzell A; Paredes R; Coakley E; Nijs S; Clotet B; Petropoulos CJ; Schapiro J; Huang W; Picchio G
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2872-9. PubMed ID: 21464253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
    Di Vincenzo P; Rusconi S; Adorni F; Vitiello P; Maggiolo F; Francisci D; Di Biagio A; Monno L; Antinori A; Boeri E; Punzi G; Perno CF; Callegaro A; Bruzzone B; Zazzi M;
    HIV Med; 2010 Sep; 11(8):530-4. PubMed ID: 20236364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
    Scott C; Grover D; Nelson M
    AIDS; 2008 May; 22(8):989-90. PubMed ID: 18453859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.
    McCormick KD; Penrose KJ; Brumme CJ; Harrigan PR; Viana RV; Mellors JW; Parikh UM; Wallis CL
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.